血清E-cadherin、HMGB1水平在卵巢癌中的价值及其与化疗疗效的关系  

The value of serum E-cadherin and HMGB1 in ovarian cancer and its relationship with chemotherapy efficacy

作　　者：徐晨 黄丽霞 XU Chen;HUANG Lixia(Department of Gynaecology and Obstetrics,the No.3 People′s Hospital of Liaocheng,Shandong 252000,China;Department of Gynaecology, Liaocheng Central Hospital,Shandong 252000,China)

机构地区：[1]聊城市第三人民医院妇产科,山东聊城252000 [2]聊城市中心医院妇科,山东聊城252000

出　　处：《国际检验医学杂志》2018年第3期308-311,315,共5页International Journal of Laboratory Medicine

摘　　要：目的探讨血清上皮型钙黏蛋白(E-cadherin)、高迁移率簇蛋白B1(HMGB1)在卵巢癌中的价值及其与化疗疗效的关系。方法选取2012年10月至2014年10月应用ELISA法测定80例初治卵巢癌患者行NAC化疗方案前后血清E-cadherin、HMGB1水平,并与60例健康体检者进行比,化疗后对患者随访36~60个月,分析血清E-cadherin、HMGB1水平与卵巢癌近远期疗效的关系。结果卵巢癌化疗前血清Ecadherin、HMGB1水平高于卵巢良性肿瘤及对照组,差异有统计学意义(P<0.05),而化疗后血清E-cadherin、HMGB1水平低于化疗前,但仍高于对照组,差异有统计学意义(P<0.05)。化疗后CR+PR组血清E-cadherin、HMGB1水平低于化疗前,差异有统计学意义(P<0.05),且与对照组相当;而SD+PD组患者血清E-cadherin、HMGB1水平明显高于对照组及CR+PR组,差异有统计学意义(P<0.05)。患者化疗后E-cadherin、HMGB1水平与临床分期、肿瘤大小及淋巴结转移有关(P<0.05),经Cox风险模型分析可知,肿瘤临床分期、淋巴转移、化疗后E-cadherin>2.10mg/L、化疗后HMGB1>115μg/mL是卵巢癌无进展生存期的独立危险因素(P<0.05)。结论化疗前后动态监测血清E-cadherin、HMGB1水平将有助于评价卵巢癌预后情况及复发情况,为下一步治疗提供指导。Objective To investigate the value of E-cadherin and HMGB1 in ovarian cancer and its relationship with the curative effect of chemotherapy.Methods The levels of E-cadherin and HMGB1 of 80 cases of newly diagnosed ovarian cancer patients before and after NAC chemotherapy and 60 cases of healthy controls were measured from October 2012 to October 2014.The patients were followed up after chemotherapy 24~36 months.The relationship between serum E-cadherin and HMGB1 and the long-term efficacy of ovarian cancer was analyzed.Results The levels of serum E-cadherin and HMGB1 in ovarian cancer before chemotherapy were significantly higher than those in ovarian benign tumor and control group(P<0.05).The levels of serum E-cadherin and HMGB1 before chemotherapy were significantly lower than those before chemotherapy.The levels of serum E-cadherin and HMGB1 in CR+PR group were lower than those before chemotherapy(P<0.05),and the levels of E-cadherin and HMGB1 in SD+PD group were significantly higher than those in control group and CR+PR group(P<0.05).The level of E-cadherin and HMGB1 were correlated with clinical stage,tumor size and lymph node metastasis(P<0.05).The Cox risk model showed that E-cadherin>2.10 mg/L after chemotherapy,lymph node metastasis.After chemotherapy,HMGB1>115μg/mL was an independent risk factor for the progression-free survival of ovarian cancer(P<0.05).Conclusion The serum E-cadherin and HMGB1 levels before and after chemotherapy will help to evaluate the prognosis and recurrence of ovarian cancer,and provide guidance for the next treatment.

关 键 词：上皮型钙黏素 高迁移率簇蛋白B1 卵巢癌 化疗疗效 相关性 

分 类 号：R446.1[医药卫生—诊断学]